Checking Blood Sugar Levels in People With Pancreatic Cancer
Tests blood sugar monitoring with blood draws in adults with pancreatic cancer during treatment.
Plain-language title generated from the registry record
Registry title: Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
Key facts
- Where
- Toronto and Vancouver, CanadaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic ductal adenocarcinoma that has spread, who are about to start their first systemic cancer treatment. Blood sugar will be checked before each treatment cycle.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Pancreatic ductal adenocarcinoma (PDAC) with spread to distant sites or lymph nodes, measurable or evaluable by RECIST 1.1, ECOG performance status 0-1
- Earlier treatment
- Planned first-line systemic therapy. No earlier systemic treatment for metastatic PDAC. Adjuvant chemotherapy after surgery for early disease is allowed. Not currently receiving anti-cancer therapy.
Main reasons for not taking part
- No spread to distant sites or lymph nodes, including borderline resectable or locally advanced PDAC
- Brain metastases
- Known type I diabetes with strict glucose control already needed
- Known type II diabetes already followed by an endocrinologist
- Positive pregnancy test
Read by machine on 9 November 2026.
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaTaking people
- British Columbia CancerVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- British Columbia Cancer Agency
- Trial code
- NCT05132244
- Record updated
- 14 September 2026
- Original description
This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer. Sugar levels will be monitored with blood draws prior to each cycle of anti-cancer treatment until treatment ends or the participant's cancer worsens. Participants may receive any first-line systemic therapy for pancreatic cancer, including treatments given as part of another clinical trial. If treatment is needed to manage blood sugar levels, the treatment will be given according to the standard of care. All participants will be enrolled into the same group.Read full original descriptionShow less
Pancreatic Cancer Glucose Assessment and Regulation Study
This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer. Sugar levels will be monitored with blood draws prior to each cycle of anti-cancer treatment until treatment ends or the participant's cancer worsens. Participants may receive any first-line systemic therapy for pancreatic cancer, including treatments given as part of another clinical trial. If treatment is needed to manage blood sugar levels, the treatment will be given according to the standard of care. All participants will be enrolled into the same group.
Inclusion: Histological/cytological diagnosis of pancreatic ductal adenocarcinoma (PDAC); Planned to undergo first-line systemic therapy; Age greater than or equal to 18 years; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Adequate bone marrow and organ function as defined by the following laboratory values:; Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\^9/L; Platelet count greater than or equal to 75 x 10\^9/L; Hemoglobin greater than or equal to 9.0 g/dL; Estimated glomerular filtration rate (GFR) by Cockroft-Gault equation OR 24 hour urine collection greater than or equal to 40 ml/min; Creatinine clearance greater than or equal to 40 mL/min using Cockcroft-Gault formula; Potassium within normal limits, or corrected with supplements; International normalized ratio (INR) less than or equal to 1.5; Total serum bilirubin less than or equal to 2 x upper limit of normal (ULN) (any elevated bilirubin should be asymptomatic at enrollment) except for participants with documented Gilbert's syndrome who may only be included if the total bilirubin less than or equal to 3 x ULN or direct bilirubin less than or equal to 1.5 x ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN (or less than or equal to 5 x ULN if liver metastases are present); Able to understand and voluntarily sign the informed consent form; Able to comply with the study visit schedule and other protocol requirements; Able to swallow oral medications; Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 at baseline; Life expectancy of more than 90 days as judged by the study doctor.
Exclusion: Received prior systemic therapy (chemotherapy or any other anti-cancer agent) for treatment of metastatic PDAC. Participants who received adjuvant chemotherapy after surgical resection of early stage disease are eligible; Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent); Known diagnosis of type II diabetes and already followed by Endocrinologist; Known diagnosis of type I diabetes where strict glucose control and close Endocrinology follow-up is already indicated; Absence of distant or lymph node metastases. Participants with borderline resectable or locally advanced PDAC are not eligible; Presence of brain metastases; Participants with a positive pregnancy test; Participants who are not safe to include in the study as judged by the study doctor for any medical or non-medical reason; Unable to comply with study assessments and follow-up.